In This Article:
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
The Food and Drug Administration on Tuesday approved a new treatment for a rare skin condition, teeing up a commercial battle between two cell and gene therapy developers.
The agency cleared Abeona Therapeutics’ Zevaskyn for a form of epidermolysis bullosa, a rare disease that makes the skin susceptible to extensive and severe blistering. On a conference call, CEO Vishwas Seshadri disclosed the therapy — a one-time treatment made from a person’s skin cells — will cost $3.1 million at list price, making it one of the world’s most expensive medicines.
Abeona will reimburse insurers an unspecified percentage of the Zevaskyn’s cost if a treated wound needs additional therapy within three years, he said.
There are several types of epidermolysis bullosa, or EB, an inherited condition that, according to some estimates, affects up to 50,000 people in the U.S. The most severe version is the recessive form of “dystrophic” disease, in which chronic blistering begins at birth or shortly afterwards and covers much of the skin, causing recurrent scarring, difficulty eating and other health problems.
EB is typically managed through supportive care. However, in 2023, a topical gene therapy from Krystal Biotech was approved for people with the dystrophic form of the disease. That product, Vyjuvek, is administered weekly through a topical gel instead of a long-lasting skin graft and costs an estimated $631,000 per year. It’s off to a strong sales start, making Krystal one of the few gene therapy developers to succeed commercially. Shares have more than doubled since Vyjuvek’s approval, giving Krystal a market value of nearly $5 billion.
Abeona is positioning Zevaskyn as an alternative option, referring to it in a statement as the only FDA-approved product to treat disease-related wounds with a “single application.”
The company is counting on the drug to help it break even financially next year. Zevaskyn’s approval also came with a special FDA voucher that Abeona can sell.
Yet investors have been skeptical of Abeona’s prospects because of the competition it faces from Krystal’s gene therapy. Its stock trades around $5 per share and fell 5% Tuesday morning following news of the approval.
Some Wall Street analysts are optimistic Abeona’s value will grow, though. In a report last year, analysts at the investment firm Stifel wrote Krystal and Abeona’s therapies may be “more complementary than competitive,” since Vyjuvek likely isn’t a “one-size-fits-all” treatment.